Research across Non-Hodgkin's Lymphoma
Related studies from across the Non-Hodgkin's Lymphoma family.
Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients
Nursing Program Reduces Fall Risk for Lymphoma Patients
This randomized controlled trial of 210 older adults with non-Hodgkin's lymphoma found that a multifaceted preventive nursing program signif…
A specialized nursing program significantly reduced falls and improved mobility for older adults undergoing chemotherapy for lymphoma.
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis
Gene Variants Linked to Higher Non-Hodgkin Lymphoma Risk
This meta-analysis of 53,864 cases and 60,448 controls found that certain IL-10 polymorphisms (rs1800890 and rs1800896) are associated with …
Certain IL-10 gene variants may slightly raise the risk of non-Hodgkin lymphoma, a large analysis finds.
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
CAR-T cell therapy shows improved survival for certain blood cancers
This meta-analysis of 2150 adult patients with relapsed or refractory diffuse large B-cell lymphoma found that CAR-T cell therapy significan…
New analysis shows CAR-T cell therapy significantly improves survival and response rates for patients with relapsed or refractory DLBCL.
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL
Overweight status linked to better survival in certain lymphoma
A meta-analysis reveals that overweight status correlates with improved survival in DLBCL, while underweight status is linked to poorer clin…
Patients with diffuse large B-cell lymphoma who are overweight may have better survival outcomes than those who are underweight.
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged
New Treatment Options Show Promise for Specific Lymphoma Patients
This network meta-analysis of 1,016 treatment-naïve patients with MYC/BCL2 double-expressor DLBCL found that Pola-R-CHP significantly reduce…
A new drug combination may reduce the risk of disease progression in patients with a specific type of lymphoma.
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma
Trial shows lenalidomide and rituximab for advanced follicular lymphoma
This Phase 3 randomized controlled trial of 1030 patients with previously untreated advanced follicular lymphoma found that the combination …
A large trial shows that a combination of two drugs can serve as an effective alternative to chemotherapy for patients with advanced follicu…
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs
Organ transplant recipients face higher risk of certain cancers
This meta-analysis of multi-centre cohort and registry-based studies indicates that solid organ transplant recipients experience significant…
People who receive heart or lung transplants face a significantly higher risk of dying from specific types of cancer.
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …